Why the target has changed

A few forces are pushing buyers toward platforms rather than single assets. Pricing pressure is intensifying across major markets, government pricing negotiations and reference pricing mechanisms are compressing margins on individual products, which is pushing acquirers toward owning more of the value chain rather than depending on any single molecule’s commercial success.

There’s also a growing pattern of buyers explicitly acquiring capabilities, in manufacturing infrastructure, delivery technology, and specialist data and diagnostic tools, where the strategic asset in the transaction is not only the product itself but the workflow, capacity, or specialist capability sitting behind it. Leading pharmaceutical companies are increasingly acquiring the capabilities for end-to-end production to reduce their exposure to the manufacturing bottlenecks that have repeatedly disrupted supply in recent years.

The logic is straightforward once you see it. A single molecule carries binary risk: it either succeeds commercially or it doesn’t. A platform, a manufacturing capability, a delivery technology, a data infrastructure, creates value across multiple products, multiple years, and multiple therapeutic areas. In an environment where pricing is under sustained pressure and patent cliffs are eroding existing revenue across the industry, platforms offer a more durable answer to where future value comes from.

What this means for integration and it’s not the same problem

This is where the shift has real operational consequences, and where it differs meaningfully from the integration challenges written about previously in the context of the broader M&A surge.

Integrating a single molecule or pipeline asset is, relatively speaking, a contained problem: a defined R&D programme, a specific regulatory pathway, a discrete commercial launch to plan around. Integrating a platform is a different order of challenge entirely. A manufacturing capability needs to be genuinely absorbed into existing operations, not run alongside them, but woven into how production, quality, and supply chain actually function day to day, often across multiple countries and regulatory jurisdictions simultaneously. A delivery technology needs to be validated and scaled across multiple product lines, not just the one it was originally developed for. A diagnostic or data platform needs to be made interoperable with existing systems and governed to a consistent standard across every market it touches.

In other words, platform acquisitions demand a much deeper, much more operational integration than asset acquisitions ever did, precisely at a moment when deal volume and pace show no sign of slowing, One widely cited tracker has recorded at least 45 acquisitions industry-wide in the first half of 2026 alone.

Where the risk actually sits

Organisations moving into platform-based dealmaking without adjusting their integration approach accordingly are taking on a specific and often underestimated risk. Due diligence built around evaluating a molecule (clinical data, regulatory pathway, competitive positioning) doesn’t map cleanly onto evaluating a platform, where the real questions are about operational scalability, cross-border regulatory compatibility, and whether the capability can genuinely be extended beyond the specific use case it was built for.

The organisations getting this right are asking a different set of questions at diligence stage. Can this manufacturing capability actually scale to our volume requirements across every market we operate in, or was it built and proven at a much smaller scale in a single jurisdiction? Are the systems and processes behind this platform genuinely interoperable with our own, or will they require a parallel infrastructure to be maintained indefinitely? Does the delivery or diagnostic technology generalise across therapeutic areas and regulatory environments, or is its value narrowly tied to the original application it was developed for?

A more strategic, more demanding era of dealmaking

Deal structures are adapting to reflect this shift too. Bolt-on acquisitions in the low single-digit billions are increasingly favoured over mega-mergers, targeting capabilities that can be integrated rapidly into existing operations while minimising integration risk. Even the deals that don’t happen tell a story, reported talks between AstraZeneca and Bristol Myers Squibb over a combination worth an estimated $400 billion, later denied by a source close to the discussions, still reflect an industry actively weighing the scale and control needed to compete on platform terms rather than pipeline terms alone.

This is, in many respects, a more disciplined era of pharma M&A than the speculative dealmaking of the past. But discipline in deal selection doesn’t automatically translate into discipline in integration. The organisations that will get genuine value from platform acquisitions are the ones treating integration planning, across every market and regulatory environment the platform touches, as a core part of the deal thesis from day one, not a workstream to be figured out once the deal is done.

Buying the platform is, in many ways, the smarter strategic move. Integrating it well, across borders and regulatory regimes, is the harder one. Closing that gap is the real work of the next generation of pharma M&A.